Difei Yang
Stock Analyst at Mizuho
(2.16)
# 2,916
Out of 5,072 analysts
33
Total ratings
31.03%
Success rate
11.79%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $1.58 | +26.58% | 4 | Mar 31, 2022 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $12.81 | +1,461.28% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $1.03 | +3,589.32% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $725 | $8.80 | +8,138.64% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $27.51 | +89.02% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $21.34 | +649.77% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $7.18 | +94.99% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $315 → $525 | $65.21 | +705.09% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.16 | - | 2 | Aug 8, 2018 | |
| RGNX REGENXBIO | Initiates: Neutral | $28 | $13.39 | +109.11% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.16 | +2,313.79% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $1.58
Upside: +26.58%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $12.81
Upside: +1,461.28%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $1.03
Upside: +3,589.32%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $725
Current: $8.80
Upside: +8,138.64%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $27.51
Upside: +89.02%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $21.34
Upside: +649.77%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $7.18
Upside: +94.99%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $315 → $525
Current: $65.21
Upside: +705.09%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.16
Upside: -
REGENXBIO
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $13.39
Upside: +109.11%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.16
Upside: +2,313.79%